KDA Group (KDA) Fair Value & Analysis
Healthcare · CA · Market cap C$14.0M
Fair value as of: Jul 31, 2026
From 1 valuation models · updated 10 days ago
Below-average quality, and screening another 58% overvalued on our models.
What matters now
- Weak quality (16/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
60‑month range C$0.0500 – C$0.6200 · the C$0.0600 price screens above the C$0.0255 fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
KDA Group (KDA) currently trades at C$0.0600, while our model-based Fair Value estimate is C$0.0255, implying the stock looks roughly 57.5% overvalued today. The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at C$317K. Revenue grew 82.4% year over year. It earns a return on equity of -88.2%. Fundamentals as of Jul 31, 2026
For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -58%, KDA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when KDA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 19 · Market factors (momentum, volatility) 11
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
KDA Group Inc., together with its subsidiaries, provides technological and operational efficiency solutions for both the general and specialized health sectors in Canada.
Full company description
KDA Group Inc., together with its subsidiaries, provides technological and operational efficiency solutions for both the general and specialized health sectors in Canada. The company offers Adherize+, which is an intelligent patient engagement platform designed to monitor treatment adherence and provide tailored interventions; Medherize, a specialized module of Adherize+, focuses on patients undergoing complex therapies such as oral oncology treatments; KRx is an advanced electronic prescription platform for medical clinics; and CareMedic is digital health record and care coordination platform. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. is headquartered in Thetford Mines, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
KDA Group reported revenue of C$165K in FY2025 versus C$24.4M in FY2021, a compound −71.3%/yr. Reported net income was −C$8.0M in FY2025.
KDA screens 58% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare KDA Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is KDA Group (KDA) overvalued or undervalued?
What is the fair value of KDA?
What is the quality score of KDA?
What is the revenue of KDA Group (KDA)?
What is the net profit margin of KDA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track KDA Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.